Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Finding and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma

NCT05655312 is registered in ClinicalTrials.gov with Perspective Therapeutics as lead sponsor.

NCT NCT05655312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Finding and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma
Lead sponsor
Perspective Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2023
Completion date
December 31, 2029
Enrollment
300 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma stage iv, metastatic melanoma, recurrent melanoma (skin)